OBSOLETE: Drug and/or toxic myopathy

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:206985
Who is this for?
Show terms as
View depth
8Treatment centers

Where are you in your journey?

UniteRare data is compiled from authoritative primary sources (FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, NORD), then processed through automated and AI-assisted extraction pipelines.
Report missing data

What is OBSOLETE: Drug and/or toxic myopathy?

Drug and/or toxic myopathy refers to muscle damage and weakness caused by exposure to certain medications, drugs, or toxic substances rather than by an inherited genetic condition. This condition occurs when a substance harms the muscle fibers, leading to muscle pain, tenderness, weakness, and sometimes muscle breakdown. Common culprits include cholesterol-lowering medications (statins), alcohol, corticosteroids, certain chemotherapy drugs, colchicine, and recreational drugs like cocaine. The severity can range from mild muscle aches to severe muscle destruction called rhabdomyolysis, which can be life-threatening if it damages the kidneys. Note that this Orphanet entry (206985) is marked as OBSOLETE, meaning it has been retired or reclassified in the Orphanet database. Patients experiencing drug-related or toxin-related muscle problems should still seek medical attention. The condition is sometimes called toxic myopathy, drug-induced myopathy, or medication-related muscle disease. Treatment primarily involves identifying and stopping the offending substance. In many cases, muscle function can recover partially or fully once the toxic agent is removed. Supportive care may include hydration, physical therapy, and pain management. In severe cases involving rhabdomyolysis, hospitalization with aggressive intravenous fluids is necessary to protect the kidneys. The outlook depends heavily on how quickly the cause is identified and removed, and on the extent of muscle damage at the time of diagnosis.

Key symptoms:

Muscle weakness, especially in the upper arms and thighsMuscle pain or sorenessMuscle tenderness when touchedMuscle crampsFatigue and tirednessDifficulty climbing stairs or rising from a chairDifficulty lifting arms above the headDark or brown-colored urine (sign of muscle breakdown)Muscle stiffnessSwelling in the affected musclesGeneral feeling of being unwellReduced exercise tolerance

Inheritance
Sporadic
Usually appears on its own, not inherited from a parent
Age of Onset
Variable
Can begin at different ages, from infancy through adulthood
Orphanet ↗NORD ↗

Treatments

Source: openFDA + DailyMed · NDA / BLA labels with structured indications · refreshed weekly

No FDA-approved treatments are currently listed for OBSOLETE: Drug and/or toxic myopathy.

View clinical trials →

Source: ClinicalTrials.gov · synced daily · phases, status, and PI names normalized at ingest

No actively recruiting trials found for OBSOLETE: Drug and/or toxic myopathy at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the OBSOLETE: Drug and/or toxic myopathy community →

Source: NPI Registry + PubMed · trial PI roles cross-referenced with ClinicalTrials.gov · ranked by match score (publications + PI activity + community signal)

No specialists are currently listed for OBSOLETE: Drug and/or toxic myopathy.

View NORD Rare Disease Centers ↗Undiagnosed Disease Network ↗

Treatment Centers

8 centers

Source: NORD Rare Disease Centers + NIH Undiagnosed Diseases Network (UDN) · centers verified active within last 12 months

🏨 Children's

Children's Hospital Colorado Rare Disease Program

Children's Hospital Colorado

📍 Aurora, CO

👤 Boston Children's Hospital Rare Disease Program

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Boston Children's Hospital Rare Disease Program

Boston Children's Hospital

📍 Boston, MA

👤 Boston Children's Hospital Rare Disease Program

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

🏨 Children's

Ann & Robert H. Lurie Children's Hospital Genetics

Lurie Children's Hospital

📍 Chicago, IL

👤 Boston Children's Hospital Rare Disease Program

🏥 NORD

Cincinnati Children's Hospital Medical Center

Cincinnati Children's

📍 Cincinnati, OH

👤 Boston Children's Hospital Rare Disease Program

🏨 Children's

Nationwide Children's Hospital Rare Disease Center

Nationwide Children's Hospital

📍 Columbus, OH

👤 Boston Children's Hospital Rare Disease Program

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

Travel Grants

No travel grants are currently matched to OBSOLETE: Drug and/or toxic myopathy.

Search all travel grants →NORD Financial Assistance ↗

Community

Open OBSOLETE: Drug and/or toxic myopathyForum →

No community posts yet. Be the first to share your experience with OBSOLETE: Drug and/or toxic myopathy.

Start the conversation →

Latest news about OBSOLETE: Drug and/or toxic myopathy

Source: PubMed + NIH RePORTER + openFDA + clinical-journal RSS · last 30 days · disease-tagged at ingest by AI extraction with human QC

No recent news articles for OBSOLETE: Drug and/or toxic myopathy.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.Which of my current medications or substances could be causing my muscle problems?,How long after stopping the medication should I expect to see improvement?,Do I need to be tested for genetic factors that make me more sensitive to certain drugs?,Are there safer alternative medications for my other health conditions?,What warning signs should prompt me to go to the emergency room?,Should I have regular blood tests to monitor my muscle enzymes during recovery?,When can I safely return to exercise and normal physical activity?

Common questions about OBSOLETE: Drug and/or toxic myopathy

What is OBSOLETE: Drug and/or toxic myopathy?

Drug and/or toxic myopathy refers to muscle damage and weakness caused by exposure to certain medications, drugs, or toxic substances rather than by an inherited genetic condition. This condition occurs when a substance harms the muscle fibers, leading to muscle pain, tenderness, weakness, and sometimes muscle breakdown. Common culprits include cholesterol-lowering medications (statins), alcohol, corticosteroids, certain chemotherapy drugs, colchicine, and recreational drugs like cocaine. The severity can range from mild muscle aches to severe muscle destruction called rhabdomyolysis, which ca

How is OBSOLETE: Drug and/or toxic myopathy inherited?

OBSOLETE: Drug and/or toxic myopathy follows a sporadic inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

Frequently asked questions about OBSOLETE: Drug and/or toxic myopathy

Auto-generated from canonical disease facts (Orphanet, OMIM, ClinicalTrials.gov, openFDA, NPPES). Not a substitute for clinical guidance.

  1. What is OBSOLETE: Drug and/or toxic myopathy?

    OBSOLETE: Drug and/or toxic myopathy is a rare disease catalogued in international rare-disease ontologies (Orphanet ORPHA:206985). It is typically inherited as sporadic. Age of onset is generally variable. For verified primary sources, see the UniteRare OBSOLETE: Drug and/or toxic myopathy page.

  2. How is OBSOLETE: Drug and/or toxic myopathy inherited?

    OBSOLETE: Drug and/or toxic myopathy follows sporadic inheritance. Genetic counseling is recommended for affected families to understand recurrence risk in offspring and the likelihood of unaffected siblings being carriers. Variants in the underlying gene(s) may be identified via clinical genetic testing.

  3. Are there FDA-approved treatments for OBSOLETE: Drug and/or toxic myopathy?

    Approved treatments for OBSOLETE: Drug and/or toxic myopathy are tracked from openFDA and DailyMed primary sources. Many rare diseases have no specific FDA-approved therapy; for those, supportive care and management of complications form the basis of clinical care. Orphan-drug-designation status is noted where applicable.

  4. Are there clinical trials for OBSOLETE: Drug and/or toxic myopathy?

    Active clinical trials for OBSOLETE: Drug and/or toxic myopathy are tracked daily from ClinicalTrials.gov. Trial availability changes frequently; check the UniteRare trial listings for the current count and recruitment status. Sponsors of rare-disease research often welcome inquiries even when a trial is not actively recruiting at a given moment.

  5. How do I find a specialist for OBSOLETE: Drug and/or toxic myopathy?

    Verified OBSOLETE: Drug and/or toxic myopathy specialists are identified through ClinicalTrials.gov principal-investigator records, peer-reviewed publication authorship (via PubMed), and the NPPES NPI registry. NORD-designated Centers of Excellence and NIH-affiliated rare-disease clinics are also tracked. UniteRare's specialist directory is updated continuously as new evidence becomes available.

See full OBSOLETE: Drug and/or toxic myopathy page for complete clinical details, sources, and verified-specialist listings.

Cite this page

Select a citation format above to view and copy.